Loading...

Home
ETF
FATE

FATE

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

FATE News

Avaí Bio Advances Cell Therapy Production Milestone

Mar 03 2026PRnewswire

Avaí Bio Advances α-Klotho Cell Production Milestone

Mar 03 2026Newsfilter

Fate Therapeutics Reports Q4 2025 Revenue and Financial Position

Feb 26 2026seekingalpha

FT819 CAR T-Cell Therapy Achieves Significant Milestone

Feb 26 2026Newsfilter

Fate Therapeutics Inc. Forecasts Operating Runway Until End of 2027, Backed by $205 Million in Cash and Investments

Feb 26 2026moomoo

Momentum in iPSC-Derived NK Cells Clinical Trials: 12+ Companies Innovate

Feb 16 2026Newsfilter

Avant Technologies Leads Transformation in Healthcare Market

Jan 26 2026PRnewswire

Avant Technologies Leads Medical Innovation with Next-Gen Treatments

Jan 26 2026Newsfilter

Avant Technologies Unveils Cell Encapsulation Tech to Address 589 Million Diabetes Patients' Needs

Jan 23 2026Globenewswire

Avant Technologies Unveils Cell Encapsulation Tech, Tapping into Diabetes Market Potential

Jan 23 2026Newsfilter

Needham Maintains Hold Rating on Fate Therapeutics

Oct 27 2025Benzinga

Fate Therapeutics Unveils New Clinical Findings at ACR Convergence 2025 Highlighting Immune Remodeling and Lasting Responses in Systemic Lupus Erythematosus Patients Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Oct 26 2025Newsfilter

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

Aug 14 2025Newsfilter

Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down

May 30 2025NASDAQ.COM

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30 2025Newsfilter

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 28 2025Newsfilter